🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

IDEXX Laboratories, Inc. IDXX NDXSPX

Healthcare · Diagnostics & Research · United States
https://www.idexx.com

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

READ MORE ›
$563.53
+9.77% 1Y

Market & Price

Market Cap
$44.45B
Current Price
$563.53
High / Low (52W)
$766.68 / $513.36
Beta
1.57

Valuation

Stock P/E
41.50
Industry PE
23.65
Forward P/E
34.12
PEG Ratio
3.61
Book Value
$20.14
Price to Book
27.98
P/S
10.00
EV/EBITDA
29.34
Dividend Yield
-

Profitability & Returns

ROCE
61.90%
ROE
72.91%
ROA
26.46%
Profit Margin
24.63%
Op Margin
31.78%
EPS (Latest Qtr)
$3.47
EPS (TTM)
$13.58

Balance Sheet & Liquidity

Debt/Equity
0.71
Quick Ratio
0.69
Current Ratio
1.12
Debt
$1.11B
Total Assets
$3.35B
Current Assets
$1.41B
Working Capital
$265.01M

Ownership

Promoter Holding
0.69%
Chg in Prom Hold
-
FII / Inst Holding
96.24%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$45.36B
Total Revenue (TTM)
$4.45B
EBITDA
$1.55B
Free Cash Flow
$786.84M
Operating Cash Flow
$1.21B
Shares Outstanding
78.88M
Gross Margin
62.05%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
8.52%
Profit 5Y
15.98%
Revenue (YoY)
14.30%
Earnings (YoY)
17.20%

PROS

  • Strong return on equity of 72.9%.
  • Healthy ROCE of 61.9%.
  • Excellent profit margin of 24.6%.
  • Profit CAGR of 16.0% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 26.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IDXX IDEXX Laboratories, Inc. NDXSPX 563.53 41.50 $44.45B - 61.90% 72.91% 8.52% 15.98%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------462.02M508.94M491.98M506.12M537.66M580.75M545.45M549.39M576.06M620.10M605.30M605.45M626.34M637.59M721.79M777.71M826.14M810.42M836.55M860.55M841.66M900.20M943.63M915.53M964.10M1.00B975.54M998.43M1.11B1.11B1.09B1.14B
Cost of Revenue -----------------------------------375.05M414.73M421.88M432.46M418.08M
Gross Profit 215.54M232.76M224.27M217.69M227.54M260.54M246.73M240.63M258.19M292.71M274.00M272.47M303.10M332.44M305.64M300.36M331.60M357.85M344.95M331.15M359.59M379.34M422.61M470.78M489.31M472.92M498.75M514.03M506.63M542.97M572.85M547.98M593.07M619.16M596.04M623.38M694.73M683.35M658.11M722.74M
Operating Expenses -----------------------------------306.85M321.69M328.51M342.51M360.15M
Operating Income 72.80M88.30M71.89M66.91M73.79M104.16M88.46M83.83M92.24M122.56M100.41M97.81M113.04M145.59M117.35M115.35M133.14M164.28M139.80M115.63M144.32M193.25M171.86M247.62M259.25M225.96M248.34M179.07M244.83M280.40M296.14M275.28M298.96M263.80M303.89M316.53M373.05M354.85M315.61M362.59M
EBITDA -----------------------------------351.81M409.44M392.05M354.91M400.87M
Interest Expense -----------------------------------7.67M11.32M10.65M9.21M7.74M
Pretax Income -----------------------------------310.08M362.35M344.77M306.98M355.44M
Tax Provision -----------------------------------67.41M68.36M70.16M58.79M77.00M
Net Income 46.59M56.91M44.22M44.35M46.02M67.20M56.45M52.37M69.02M85.36M70.51M38.26M89.45M108.69M93.25M85.64M102.68M125.71M108.84M90.50M111.83M148.94M146.22M204.26M202.58M175.24M193.97M131.98M180.94M214.05M224.24M212.23M235.58M203.30M232.84M242.68M293.99M274.61M248.19M278.45M
Diluted EPS 0.490.600.480.480.510.740.620.580.770.950.790.431.011.231.050.981.171.431.241.041.291.721.692.352.342.032.271.562.152.552.672.532.812.442.802.963.633.403.083.47
R&D Expense 25.01M24.32M24.86M-24.62M25.41M25.67M-25.79M27.00M27.59M-29.02M29.51M29.19M-31.51M32.26M34.26M-33.31M31.64M37.52M37.58M37.70M40.43M40.17M123.22M48.01M44.67M46.51M47.97M52.63M55.45M53.98M59.06M61.90M63.41M-65.79M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------1.78B1.97B2.21B2.41B2.71B-3.37B3.66B3.90B4.30B
Cost of Revenue --------------1.36B1.47B1.52B1.64B
Gross Profit 529.77M526.28M578.62M646.51M699.15M756.12M816.12M890.27M975.44M1.10B1.24B1.37B1.57B-2.00B2.19B2.38B2.66B
Operating Expenses --------------1.11B1.09B1.25B1.30B
Operating Income 172.46M175.97M203.88M236.22M262.56M266.76M260.25M299.91M350.24M413.03M491.33M552.85M694.52M-898.76M1.10B1.13B1.36B
EBITDA --------------1.01B1.22B1.27B1.51B
Interest Expense --------------39.86M41.58M31.20M38.85M
Pretax Income --------------859.97M1.06B1.11B1.32B
Tax Provision --------------180.88M216.13M221.96M264.73M
Net Income 116.17M122.22M141.28M161.79M178.27M187.80M181.91M192.08M222.04M263.14M377.03M427.72M581.78M-679.09M845.04M887.87M1.06B
Diluted EPS 1.872.012.372.783.171.741.792.052.442.944.264.896.71-8.0310.0610.6713.08
R&D Expense 70.67M65.12M68.60M76.04M82.01M88.00M98.26M99.68M101.12M109.18M117.86M133.19M141.25M161.01M254.82M190.95M219.79M251.21M

Compounded Sales Growth

5 Years:8.52%
1 Year:14.30%

Compounded Profit Growth

5 Years:15.98%
1 Year:17.20%

Stock Price Performance

1 Year:+9.77%
6 Months:-26.50%
3 Months:-14.19%
1 Month:+1.78%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Jan 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --808.53M897.14M1.03B1.10B1.23B1.38B1.47B1.53B1.71B1.74B1.54B1.62B1.83B2.29B-2.75B3.26B3.29B3.35B
Current Assets -----------------1.10B1.50B1.40B1.41B
Cash & Equivalents 60.36M78.87M106.73M156.91M183.90M223.99M279.06M322.54M128.99M154.90M187.68M-123.79M-90.33M383.93M-112.55M453.93M288.27M180.07M
Inventory -----------------367.82M380.28M381.88M377.76M
Receivables -----------------400.62M457.44M473.57M552.38M
Total Liabilities --293.95M322.86M491.22M467.35M712.30M1.27B1.56B1.64B1.77B1.80B1.55B1.63B1.65B1.66B-2.14B1.78B1.70B1.75B
Current Liabilities --256.31M285.11M436.88M406.33M478.35M820.91M856.76M934.57M1.00B-770.44M784.22M725.34M582.76M-1.24B951.55M1.07B1.15B
Long Term Debt --------------698.91M858.49M-694.39M622.88M449.79M374.84M
Total Debt -----------------1.47B1.07B986.95M976.06M
Total Equity --514.57M574.24M539.58M636.22M518.19M117.52M-84.12M-108.35M-54.11M--9.51M-177.47M632.09M-608.74M1.48B1.60B1.61B
Shares Outstanding -----------------107.19M107.51M107.84M108.37M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 143.31M174.95M178.83M217.91M222.41M246.00M235.85M--373.28M400.08M459.16M648.06M-542.98M906.51M929.00M1.18B
Investing Cash Flow -91.59M-53.62M-43.19M-94.21M-58.13M-86.06M-80.41M---138.69M138.60M-205.53M-109.38M--195.35M-125.25M-207.06M-136.24M
Financing Cash Flow -30.79M-95.30M-86.77M-97.66M-125.34M-102.45M-103.44M---208.02M-597.80M-286.41M-248.42M--370.94M-442.00M-878.07M-1.16B
Capital Expenditure -89.97M-50.66M-38.91M-49.68M-57.62M-77.61M-60.52M-82.92M-64.79M-74.38M-115.75M-154.97M-106.96M--158.84M-133.63M-130.92M-138.23M
Free Cash Flow 53.34M124.29M139.93M168.24M164.79M168.38M175.32M--298.89M284.33M304.19M541.11M-384.15M772.88M798.08M1.04B
Net Change in Cash ---------------23.30M339.26M-156.13M-119.40M
Share Buybacks 132.34M83.10M143.09M255.50M132.27M367.76M618.16M401.98M304.09M282.56M369.32M301.66M182.81M746.78M819.71M71.92M837.03M1.22B

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------54.9%55.7%56.1%56.7%58.0%-59.5%59.8%61.0%61.8%
Operating Margin % --------19.7%21.0%22.2%23.0%25.7%-26.7%30.0%29.0%31.6%
Net Margin % --------12.5%13.4%17.0%17.8%21.5%-20.2%23.1%22.8%24.6%
ROE % -23.8%24.6%30.0%28.0%36.2%154.8%-228.3%-204.9%-486.3%-3,963.3%241.0%92.0%-111.6%56.9%55.7%66.0%
ROCE % -31.9%33.3%39.8%37.7%35.5%46.2%48.5%58.8%58.3%64.1%49.9%40.6%-59.5%47.5%50.7%61.8%

Shareholding Pattern

Insiders
0.69%
Institutions
96.24%
Public Float
96.91%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 10.61% 8.37M $4.71B
2 Vanguard Capital Management LLC 6.57% 5.18M $2.92B
3 Vanguard Portfolio Management LLC 4.96% 3.91M $2.20B
4 State Street Corporation 4.66% 3.67M $2.07B
5 Geode Capital Management, LLC 3.37% 2.66M $1.50B
6 Invesco Ltd. 2.13% 1.68M $945.92M
7 BAMCO Inc. 2.07% 1.63M $920.45M
8 Bank Of New York Mellon Corporation 1.91% 1.50M $847.85M
9 Fundsmith LLP 1.86% 1.47M $826.01M
10 Morgan Stanley 1.67% 1.32M $741.58M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IDXX

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space